Summary

Your MTHFR C677T result determines how efficiently you convert folic acid into its active form (methylfolate), directly affecting over 200 methylation reactions including neurotransmitter production, DNA repair, and homocysteine clearance — and the TT genotype is one of the most actionable genetic findings you can have.

Genotype spectrum

CC (Wild type)

Full methylation capacity. Your folate metabolism is efficient — folic acid and food folate both work well for you.

CT (Heterozygous)

You're in the largest group — this is extremely common and usually clinically silent with adequate nutrition. You have meaningful enzyme function remaining.

TT (Homozygous)

This is one of the highest-leverage genetic findings — interventions (methylfolate, riboflavin, dietary folate) produce outsized effects because your baseline is lower. The gap between your "unoptimised" and "optimised" state is larger than for most people.

Practical takeaway

For TT Carriers (Priority Tier — High Leverage)

Start here (Week 1):
• Methylfolate (5-MTHF): 400-800 mcg/day. Start at 400 mcg. Quatrefolic or Metafolin are well-studied branded forms. Take with food.
• Riboflavin (B2): 1.6 mg/day. This is the specific dose from the McNulty blood pressure RCTs. Cheap, safe, and genotype-targeted.
• Methylcobalamin (B12): 1000 mcg/day. The methionine synthase (MTR) reaction that clears homocysteine needs B12. Using the methyl form ensures you're not adding to methylation demand.
• Dietary folate: Prioritise leafy greens (spinach, kale, broccoli), legumes (lentils, chickpeas, black beans), and liver (if tolerated). These provide natural folate that enters the pathway downstream of the bottleneck.

Then add (Month 2+):
• Homocysteine blood test: Baseline, then at 3 months. Optimal range: <10 μmol/L. If >12, discuss with GP.
• B6 (P5P form): 25-50 mg/day. Supports the transsulfuration pathway (homocysteine → cystathionine → cysteine) — an alternative homocysteine clearance route that bypasses MTHFR entirely.

Avoid or minimise:
• High-dose synthetic folic acid (>400 mcg/day from supplements). Food fortification is unavoidable and fine — it's the stacking of fortified foods + folic acid supplements that creates UMFA concerns.
• Folic acid as your sole supplemental folate form. Switch to methylfolate or add methylfolate alongside.

What "working" looks like:
• Homocysteine below 10 μmol/L (blood test at 3 months)
• Subjective: improved energy, mood stability, mental clarity (these are soft markers — homocysteine is the hard marker)
• If hypertensive: blood pressure improvement within 16 weeks (the riboflavin RCT timeline)

Expected response window: 8-16 weeks for measurable homocysteine change. Mental health effects (if applicable) may take 8-12 weeks, consistent with methylfolate/SSRI adjunct trial timelines.
For CT Carriers (Moderate Attention)
• Ensure dietary folate adequacy (400+ mcg/day from food)
• Methylfolate supplements are reasonable but not urgent
• Riboflavin (1.6 mg/day) is a sensible addition, especially if hypertensive
• Test homocysteine if other cardiovascular risk factors are present
• This becomes higher priority

Evidence detail

What This Gene Does

MTHFR produces the enzyme that converts dietary folate and synthetic folic acid into 5-methyltetrahydrofolate (5-MTHF, or methylfolate) — the only form of folate your body can actually use for methylation. Methylation is not one process; it's a family of over 200 biochemical reactions that regulate everything from neurotransmitter synthesis (serotonin, dopamine, norepinephrine) to DNA repair, detoxification, and cardiovascular protection via homocysteine clearance.

The C677T variant (a cytosine-to-thymine swap at position 677) produces a thermolabile enzyme with reduced activity. The degree of reduction depends on whether you carry one or two copies of the T allele.

Mechanism

The MTHFR enzyme sits at a critical junction in one-carbon metabolism. Here's the pathway in plain language:

1. You eat folate (from food) or folic acid (from supplements/fortified foods).
2. Both get converted through several steps into 5,10-methylenetetrahydrofolate.
3. MTHFR converts this into 5-methyltetrahydrofolate (methylfolate) — this is the rate-limiting step.
4. Methylfolate donates its methyl group to homocysteine, converting it to methionine (via MTR enzyme + B12 cofactor).
5. Methionine becomes SAM (S-adenosylmethionine) — the universal methyl donor that runs 200+ methylation reactions.
6. SAM donates its methyl group and becomes SAH, then homocysteine again — completing the cycle.

Why the C677T variant matters mechanistically:

The T allele produces a version of MTHFR that loses its FAD cofactor (derived from riboflavin/B2) more easily at body temperature. This is called "thermolability." The enzyme literally falls apart faster. In TT carriers, this means:
• Less methylfolate produced → less methyl donation to homocysteine
• Homocysteine accumulates → cardiovascular risk marker rises
• Less SAM produced → reduced methylation capacity across all downstream reactions
• Less BH4 recycling → reduced neurotransmitter synthesis capacity (serotonin, dopamine, norepinephrine)

Why riboflavin is the underappreciated cofactor:

Because the mutant enzyme loses FAD faster, supplying more FAD (via riboflavin/B2) partially stabilises the enzyme. This is why McNulty's RCTs show TT-specific responses to riboflavin — you're compensating for the structural instability, not just adding more substrate. This is a fundamentally different mechanism from methylfolate supplementation, and the two interventions are complementary.

Why folic acid still works (but less well):

The enzyme is reduced, not absent. TT carriers retain ~30% activity. Flooding the pathway with substrate (folic acid) partially compensates — more input, same (reduced) throughput, still more output than without supplementation. The CDC is correct that folic acid "works." They're incorrect to imply the bottleneck doesn't matter, especially in contexts of low riboflavin or B12 status where the remaining 30% is further compromised.

MTHFR C677T

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (17)